All Brands Owned by Takeda Pharmaceutical Company

Prescription antibody-drug conjugate treatment for classical Hodgkin lymphoma and CD30-expressing peripheral T-cell lymphomas, co-developed by Seagen and licensed to Takeda Pharmaceutical.

Prescription stem cell therapy originally approved in Europe for treating complex perianal fistulas in adult Crohn's disease patients, developed by TiGenix and acquired by Takeda.

Bausch Health's branded azathioprine tablet (75 mg and 100 mg strengths), distributed by Salix Pharmaceuticals (a division of Bausch Health US, LLC) and manufactured by Alcami Corporation, indicated for renal transplant rejection prevention and severe rheumatoid arthritis, based on the immunosuppressant azathioprine originally developed by Nobel laureate Gertrude Elion at Burroughs Wellcome in the 1950s.

Prescription medication for treating hepatic sinusoidal obstruction syndrome, manufactured and marketed by Takeda Pharmaceutical Company.

Prescription proton pump inhibitor for treating acid reflux and gastroesophageal reflux disease, manufactured and marketed by Takeda Pharmaceutical Company.

Takeda's oral proteasome inhibitor (ixazomib citrate), FDA approved November 20, 2015, as the first and only oral proteasome inhibitor approved for multiple myeloma, used in combination with lenalidomide and dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received at least one prior therapy, based on the TOURMALINE-MM1 Phase 3 trial.

Takeda's selective melatonin MT1 and MT2 receptor agonist (ramelteon) for insomnia, FDA approved July 22, 2005, as the first prescription sleep aid with no abuse potential and no DEA scheduling, indicated for sleep-onset insomnia in adults, available as an 8 mg film-coated tablet taken 30 minutes before bedtime.

United Therapeutics' inhaled treprostinil solution (prostacyclin analog), FDA approved July 30, 2009, for pulmonary arterial hypertension (PAH, WHO Group 1), with a second FDA approval in April 2021 for pulmonary hypertension associated with interstitial lung disease (PH-ILD, WHO Group 3), and a dry powder inhaler formulation (Tyvaso DPI) approved in May 2022.

Takeda's non-purine selective xanthine oxidase inhibitor (febuxostat) for chronic gout, originally discovered by Teijin Pharma in Japan, FDA approved in February 2009, subject to a black box warning added in February 2019 for increased risk of cardiovascular death and all-cause mortality compared to allopurinol based on the CARES trial, with use now restricted to patients who have failed or cannot tolerate allopurinol.

Takeda's once-daily amphetamine prodrug (lisdexamfetamine dimesylate) for ADHD and binge eating disorder, originally developed by New River Pharmaceuticals and acquired by Shire in 2007 (the year of FDA approval), with Takeda inheriting the brand through its $62 billion acquisition of Shire in 2019, before generic lisdexamfetamine was approved in 2023.